OpenAI acquires Orchestra Bio to build drug-development AI agents
OpenAI is acquiring the startup Orchestra Bio and plans to merge it into its life-sciences AI platform Rosalind. The combined effort aims to build AI agents that help pharma teams coordinate drug development, including tracking trials and spotting problems. OpenAI already works with Novo Nordisk and Moderna on AI-driven pharma research.
AI Brief
It signals a concrete OpenAI acquisition and product direction in life-sciences AI agents, which is useful for readers tracking AI in drug development.
OpenAI is acquiring startup Orchestra Bio and plans to merge it with its life sciences AI platform Rosalind. The goal is to build AI agents that help pharma teams coordinate drug development, from tracking trials to spotting problems. Developing a new drug in the US takes ten to 15 years on aveRAGe. OpenAI already works with Novo Nordisk and Moderna on AI-driven pharma research.
Comments & Questions (0)
No comments yet
Be the first to comment!